• Zetagen identifies two concentrations of Zeta-MBC-005 which were most effective in treating metastatic breast cancer in the liver
• Zeta-MBC-005 showed a significant decrease in tumor volume (4-fold) vs. control Doxorubicin
• Zeta-MBC-005 demonstrated an increased survival rate (3.9-fold) over control with no lung metastases. Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, minimizing patient side effects with the potential to increase survival rates, announced today in-vivo results of their dose optimization study of ZetaMAST™ (Zeta-MBC-005).  Zetagen identified two concentrations of Zeta-MBC-005 which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin. 

“Patients with metastases to the liver can benefit from local therapies to the liver in terms of symptoms, but it does not seem to impact on other areas of disease or prolong survival.  ZetaMAST™ is an innovative approach that also produces a systemic biological effect in preclinical models and hold the potential to improve outcomes for this situation,” stated Debasish Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

“These in-vivo results are promising and I look forward to seeing ZetaMAST™ (Zeta-MBC-005) move into Phase 1b clinical trials and possibly benefit those patients afflicted with metastatic breast cancer in the liver.,” stated Bryan S. Margulies, MS, Ph.D., CSO of Zetagen.

To view the ZetaMAST™ (Zeta-MBC-005) dose optimization study results go to https://www.biorxiv.org/search/zetagen.